Clexio Biosciences

Company Overview

Snapshot

Founded in March 2018 by Elisabeth Kogan and Menashe Levy, Clexio Biosciences operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on developing CNS therapies.

Business overview

Clexio Biosciences is a clinical-stage pharmaceutical company specializing in the development of Central Nervous System (CNS) therapies. The company's core technology involves a scientifically based fusion of drugs and innovative technologies to address unmet patient needs. Clexio Biosciences serves the pharmaceutical market, focusing on a wide range of neurological and psychiatric conditions, including major depressive disorder, Parkinson's disease, and pain, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

When was Clexio Biosciences founded?

Clexio Biosciences was founded in March 2018.

Who are the founders of Clexio Biosciences?

Elisabeth Kogan and Menashe Levy are the co-founders of Clexio Biosciences.

What is Clexio Biosciences' primary focus?

Clexio Biosciences focuses on developing CNS therapies designed to address unmet patient needs through a scientifically based fusion of drugs and innovative technologies.

What conditions does Clexio Biosciences' pipeline target?

Clexio Biosciences' pipeline is focused on developing treatments for neurological and psychiatric conditions, including major depressive disorder, Parkinson's disease, and pain.

What is the current stage of Clexio Biosciences' product development?

Clexio Biosciences' products are currently in the Clinical Trial stage, with a pipeline that includes CLE-400 and CLE-500